Fig. 1.
OS of DLCL patients with Bax-immunonegative and -immunopositive tumors. OS, comparing patients whose tumors contained less than 1% Bax-immunostained malignant cells (n = 7) with those that were Bax-immunopositive (n = 106; P = .06).
OS of DLCL patients with Bax-immunonegative and -immunopositive tumors. OS, comparing patients whose tumors contained less than 1% Bax-immunostained malignant cells (n = 7) with those that were Bax-immunopositive (n = 106; P = .06).
